*NEW* Virtual Registration options are available!
The past 24 months has seen unprecedented investment in innovation of mental health care investment area in digital health. In order to create real value for patients, all stakeholders within the mental health ecosystem need to align and collaborate.
This Conference is the first of its kind that brings together key stakeholders from all domains in mental health: research, biotech, digital health, providers, investors, and payers. As one of the top psychiatry departments in the world, Massachusetts General Hospital is uniquely positioned to host this gathering of thought leaders.
How do we get past the hype to envision better care?
A key first step is understanding what the future could look like, and what would need to happen to make it a reality.
K E Y N O T E S P E A K E R S
Thomas R. Insel, MD
Acting Director, National Center for Advancing Translational Sciences
Director, National Institute of Mental Health
Tom lnsel, M.D., a psychiatrist and neuroscientist, has been a national leader in mental health research, policy, and technology. From 2002-2015, Dr. Insel served as Director of the National Institute of Mental Health (NIMH). More recently, he led the Mental Health Team at Verily (2015-2017); co-founded Mindstrong Health (2017-2019), a start-up building tools for people with serious mental illness; and served as a special advisor to California Governor Gavin Newsom (2019), helping on behavioral health issues. In 2020, he co-founded Humanest Care, a therapeutic online community for recovery. In 2022, he joined Vanna Health as a co-founder and executive chair. Vanna Health is a start-up helping people with serious mental illness engage in psychosocial supportive care. He currently serves on the boards of Foundation for NIH, Fountain House, Schaeffer Center for Health Policy, and the Steinberg Institute (Chair, 2019-2022) as well as being an advisor to several mental health start-ups (including Alto Neuroscience, Cerebral, Compass Pathways, Owl Insights, Koa Health, Valera Health).
He is the author of Healing: Our Path from Mental Illness to Mental Health (Penguin Random House, 2022). With journalist co-founders, he launched MindSite News (www.mindsitenews.org), a non-profit digital publication focused on mental health issues. Dr. Insel is a member of the National Academy of Medicine and has received numerous national and international awards including honorary degrees in the U.S. and Europe.
More info at www.thomasinselmd.com.
Maurizio Fava, MD
Psychiatrist-In-Chief, Department of Psychiatry
Director, Division of Clinical Research, Mass General Research Institute
Executive Director, Clinical Trials Network & Institute
Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School
Dr. Fava obtained his MD from the University of Padova School of Medicine where he completed residency training in endocrinology. He completed residency training in psychiatry at Mass General. He founded and was Director of the hospital’s Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry.
Under Dr. Fava’s direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $95,000,000. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.
Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 800 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 600 abstracts.
Jim Yong Kim, MD, PhD
Vice Chairman & Partner, Global Infrastructure Partners
12th President, World Bank Group
Jim Yong Kim M.D., Ph.D., is Vice Chairman and Partner at Global Infrastructure Partners.
From July 2012 to February 2019, Dr. Kim served as the 12th President of the World Bank Group. Soon after he assumed that position, the organization established two goals to guide its work: to end extreme poverty by 2030; and to boost shared prosperity, focusing on the bottom 40 percent of the population in developing countries.
During Dr. Kim’s tenure, the World Bank achieved successive, record replenishments of the institution’s fund for the poorest countries and secured an historic capital increase which more than doubled its lending capacity. The WBG also launched facilities to address infrastructure needs, prevent pandemics, and help the millions of people affected by climate shocks, conflict, and violence.
A physician and anthropologist, Dr. Kim’s career has revolved around health, education, and improving the lives of the poor. Before joining the WBG, he served as the President of Dartmouth College and held professorships at Harvard Medical School and the Harvard School of Public Health. Dr. Kim also served as Director of the World Health Organization’s HIV/AIDS department and led its “3 by 5” initiative, the first-ever global goal for AIDS treatment, which greatly expanded access to antiretroviral medication in developing countries. In 1987, Dr. Kim co-founded Partners In Health, a non-profit medical organization.
Dr. Kim received a MacArthur “Genius” Fellowship, was recognized as one of America’s “25 Best Leaders” by U.S. News & World Report, and was named one of TIME magazine’s “100 Most Influential People in the World.”
Brought to you by Massachusetts General Hospital Psychiatry
MGH Psychiatry has a legacy of cutting-edge treatment and research, putting us in a unique position to host this conference.
P R I C I N G
Join us in-person in Boston for the inaugural Future of Mental Health conference!
In-Person Pricing:
Physicians, Psychologists, and Doctoral-level Professionals: $795.00
Other Professionals: $695.00
Students: Free
Residents & Fellows: Free
*NEW* Virtual Pricing
Physicians, Psychologists, and Doctoral-level Professionals: $695.00
Other Professionals: $595.00
Students: Free
Residents & Fellows: Free
V E N U E
We invite you to join us at The Westin Copley Place, located in the heart of Boston’s historic Back Bay.
We have arranged a special discounted rate for our valued Future of Mental Health attendees.
Please book by August 15, 2022 to enjoy this group rate.
Advance your knowledge of cutting-edge treatments and technologies! At the conclusion of this conference you will be able to confidently:
- Identify emerging technologies that may yield more effective and efficient diagnosis and treatment in mental health.
- Identify the challenges in developing and deploying these technologies in mental health.
- Describe ways in which key stakeholders can work together to overcome these challenges, by considering examples of these collaborations.
T A R G E T A U D I E N C E
This two-day conference is intended for clinicians, scientists, entrepreneurs, students, payers and investors with an interest in the future of mental healthcare.
As one of the nation’s leaders in psychiatry, Massachusetts General Hospital’s Psychiatry Department is uniquely positioned to bring together the key stakeholders in mental health to expand collective knowledge and drive the direction and future of mental health care.
S P E A K E R S
Alexandra Cantley, PhD
Partner Polaris Partners
Cristina Cusin, MD
Director, Ketamine Clinic and Associate Director, Depression Clinical and Research Program Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School
Dr. Errol B. De Souza
Executive Chairman Bionomics Ltd.
John Dunlop, PhD
Head of Research and Development Neumora Therapeutics
Amit Etkin, MD, PhD
Founder and CEO Alto Neuroscience
Marzyeh Ghassemi, PhD
Herman L. F. von Helmholtz Career Development Professor, CIFAR Azrieli Global Scholar Assistant Professor, Massachusetts Institute of Technology (MIT) in Electrical Engineering and Computer Science (EECS) and Institute for Medical Engineering & Science (IMES) CIFAR AI Chair, Vector Institute
George J. Goldsmith
Chairman, CEO and Co-Founder, COMPASS Pathways PLC
Faith Gunning, Ph.D.
Associate Professor of Psychology in Psychiatry Director of the Weill Cornell Institute of Geriatric Psychiatry Vice Chair for Research Department of Psychiatry
Peter Hames
Co-Founder and President of Big Health
Aidan Hampson PhD.
Senior Advisor on Special Projects Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse / NIH
John Herman, MD
Associate Chief and Trustees Chair of Medical Psychiatry Department of Psychiatry Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School Medical Director Employee Assistance Program MassGeneral Brigham HeathCare
Andy Keller, PhD
President and CEO Linda Perryman Evans Presidential Chair Meadows Mental Health Policy Institute
Roger Kitterman, MBA
Vice President Mass General Brigham Ventures
Emily Lattie, PhD
Assistant Professor | Dept. of Medical Social Sciences Associate Director of Training | Center for Behavioral Intervention Technologies (CBITs) Northwestern University Feinberg School of Medicine
Neil Leibowitz, MD, JD
CMO Beacon Health Options
Carl D. Marci, MD
Assistant Professor of Psychiatry, Harvard Medical School (part-time) Staff Clinician, MGH Revere Mental Health Center (part-time) Chief Psychiatrist and Managing Director, Mental Health and Neuroscience, OM1, Inc.
W. Eddie Martucci, PhD
CEO and Co-Founder, Akili
Corey M. McCann, MD, PhD
President and CEO, Pear Therapeutics, Inc
Doug Nemecek, MD, MBA
Chief Medical Officer Evernorth Behavioral Health
Steven M. Paul, MD
CEO and Chairman Karuna Therapeutics Professor of Psychiatry and Neurology Washington University School of Medicine
Roy H. Perlis, MD, MSc
Professor of Psychiatry, HMS Director, Center for Experimental Drugs and Diagnostics, MGH
Jerrold F. Rosenbaum, M.D.
Psychiatrist-in-Chief Emeritus Director, Center for the Neuroscience of Psychedelics Massachusetts General Hospital Stanley Cobb Professor of Psychiatry, Harvard Medical School
Mark Rus
Chief Executive Officer Delix Therapeutics
Stephen Smith
Cofounder and CEO of NOCD
Anthony Sossong, MD
Chief Medical Director, Behavioral Health, Amwell
Sabine Wilhelm, PhD
Chief of Psychology, Massachusetts General Hospital Director, OCD Program, Massachusetts General Hospital Chair, Digital Health Think Tank Professor, Harvard Medical School
Zayed Yasin, MD, MBA
SVP, Clinical Firsthand
Andrew Welchman, PhD
Executive Vice President, Impact, ieso
Seth D. Feuerstein, MD, JD
Faculty, Yale School of Medicine Founder and CEO, Oui Therapeutics Founder, Board Chair, Vytyl Health Senior Advisor, Athyrium Capital HQE, Department of Defense
Giuseppe Raviola, MD, MPH
Director, Mental Health, Partners In Health Director, Program in Global Mental Health and Social Change, Harvard Medical School Associate Director, The Chester M. Pierce, MD Global Psychiatry Division, MGH
Christopher M. Palmer, MD
Director, Dept. of Postgraduate and Continuing Education, McLean Hospital Assistant Professor of Psychiatry, Harvard Medical School
Solome Tibebu
Founder & Host, Going Digital: Behavioral Health Tech
Mental Health has been the #1 investment area in digital health.
In order to create real value for patients, all stakeholders within the mental health ecosystem need to align and collaborate.
D I R E C T O R S
Roy H. Perlis, MD, MSc
Professor of Psychiatry, HMS
Director, Center for Experimental Drugs and Diagnostics, MGH
Dr. Perlis is a graduate of Brown University, Harvard Medical School, and the Harvard School of Public Health. He serves as co-PI of an NIMH/NHGRI-supported Center of Excellence in Genomic Science. His lab focuses on developing clinical and genomic predictors of treatment response, and on developing novel therapeutics based on cellular models of brain disease.
David Mou, MD, MBA
Director, MGH Psychiatry’s Innovation Council
Chief Executive Officer, Cerebral
David is a psychiatrist, healthcare executive, and serial entrepreneur. He serves as the Director of MGH Psychiatry’s Innovation Council. David is the Chief Executive Officer of Cerebral, one of the largest tele-health companies that has provided high quality mental healthcare to more than 300,000 patients across all 50 states. Cerebral also works with pharmaceutical companies to pioneer decentralized clinical trials, for which David serves as Principal Investigator. Previously, David was President, Co-founder and Chief Medical Officer of Valera Health, a telehealth company that reduced unnecessary hospitalizations for patients with serious mental illness. David is on faculty at Harvard Medical School, where he has conducted research on how digital technologies can help better predict and prevent suicidal behaviors. He has been named ‘Top 10 under 35 for Healthcare’ by LinkedIn, as well as ’40 under 40′ for healthcare innovation by MedTech Boston. David graduated from Harvard College with a degree in neurobiology, and earned his MD MBA from Harvard Medical School and Harvard Business School. His writings have appeared in the New England Journal of Medicine and Stat.
Mental Health Disorders are anticipated to become the single largest healthcare burden by 2030, according to the WHO.
With over 30 years as a leader in research, clinical trials, education, and care delivery, our highly esteemed team of speakers has put together a first-of-its-kind conference to elevate the understanding of where the field of mental health is headed.
A G E N D A
D A Y O N E
September 16, 2022
7:30 AM -8:30 AM
Continental Breakfast & Registration
—
8:30 AM -8:35 AM
Welcome & Keynote Introduction
David Mou, MD; Roy Perlis, MD
—
8:35 AM – 9:00 AM
Healing: Our Path from Mental Illness to Mental Health
Thomas R. Insel, MD
Keynote Speaker
—
9:00 AM – 10:30 AM
The Future of CNS Drug Development Panel Discussion
Moderator:Roy Perlis, MD
Panelists:
Steve M. Paul, MD
Amit Etkin, MD, PhD
Errol DeSouza, PhD
John Dunlop, PhD
—
10:30 AM – 10:45 AM
Coffee Break
—
10:45 AM – 12:15 PM
The Promise and Perils of Psychedelics Panel Discussion
Moderator: Jerrold Rosenbaum, MD
Panelists:
George J. Goldsmith
Mark Rus
Cristina Cusin, MD
—
12:15 PM – 1:30 PM
Lunch Break
—
1:30 PM – 3:00 PM
How Telehealth in Transforming Mental Health Delivery Panel Discussion
Moderator: David Mou, MD
Panelists:
Seth D. Feuerstein, MD, JD
Stephen Smith
Anthony Sossong, MD
Andrew Welchman, PhD
—
3:00 PM – 3:15 PM
Coffee Break
—
3:15 PM – 4:45 PM
The Future of Digital Therapeutics Panel Discussion
Moderator: Sabine Wilhelm, PhD
Panelists:
Corey McCann, MD, PhD
Eddie Martucci, PhD
Peter Hames
Emily Lattie, PhD
Faith Gunning, PhD
—
4:45 PM
Adjourn
D A Y T W O
September 17, 2022
7:30 AM -8:30 AM
Continental Breakfast & Registration
—
8:30 AM -8:35 AM
Introduction
David Mou, MD; Roy Perlis, MD
—
8:35 AM – 9:00 AM
Maurizio Fava, MD
Keynote Speaker
—
9:00 AM – 10:30 AM
Where is Mental Health Headed? Perspectives from Investors Panel Discussion
Moderator: David Mou, MD
Panelists:
Roger Kitterman, MBA
Alexandra Cantley
Solome Tibebu
—
10:30 AM – 10:45 AM
Coffee Break
—
10:45 AM – 11:10 AM
Building the Movement for Mental Health Treatment Access: Lessons from Four Decades of Global Health Activism
Jim Yong Kim, MD, MPH
Keynote Speaker
—
11:10 AM – 12:30 PM
Rethinking Access and Quality in Behavioral Health: Perspectives from Payers Panel Discussion
Moderator: John Herman, MD
Panelists:
Neil Leibowitz, MD, JD
Doug Nemecek, MD, MBA
Giuseppe Raviola, MD, MPH
—
12:30 PM – 1:30 PM
Lunch Break
—
1:30 PM – 3:00 PM
Leveraging Data Science to Improve Mental Health
Moderator: Roy Perlis, MD
Panelists:
Marzyeh Ghassemi, PhD
Zayed Yasin, MD, MBA
Carl D. Marci, MD
Andy Keller, PhD
Christopher M. Palmer, MD
—
3:00 PM
Closing Remarks
—
3:05 PM
Adjourn
Thank you to our 2022 sponsors!
Gold:
Axsome
Silver:
Sunovion Pharmaceuticals, Inc.
Sage Therapeutics, Inc & BiogenBronze:
OM1, Inc.
Supernus Pharmaceuticals, Inc.
PsychU Otsuka
BioXcel Therapeutics Inc.S P O N S O R S H I P
We are excited to offer the opportunity to partner with Massachusetts General Hospital for our inaugural Future of Mental Health conference!
We are offering Gold, Silver and Bronze Tier sponsorship opportunities.
Sponsors will receive:
- A tabletop exhibit and number of complementary registration passes (based on sponsorship level)
- Recognition on event signage and program website
For more information about sponsoring this program contact Heather Carillo through this form or at hcarillo@mgh.harvard.edu.
